Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 1, 2015, Pages 50-59

  Bria, Emilio ^a   Massari, Francesco ^a   Maines, Francesca ^a   Pilotto, Sara ^a   Bonomi, Maria ^a   Porta, Camillo ^b   Bracarda, Sergio ^c   Heng, Daniel ^d   Santini, Daniele ^e   Sperduti, Isabella ^f   Giannarelli, Diana ^f   Cognetti, Francesco ^f   Tortora, Giampaolo ^a   Milella, Michele ^f  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Correlation; Overall survival; Progression free survival; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; FLUOROURACIL; GAMMA1B INTERFERON; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA2C INTERFERON; RECOMBINANT GAMMA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CORRELATION ANALYSIS; CYTOKINE INDUCED KILLER CELL; DRUG MEGADOSE; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; POWER ANALYSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; KIDNEY NEOPLASMS; MORTALITY; PROCEDURES; QUALITY CONTROL; STANDARDS;

ANTINEOPLASTIC AGENTS; BENCHMARKING; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84915752188     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.08.001     Document Type: Review

References (34)

1. Escudier B., Albiges L., Sonpavde G. Optimal management of metastatic renal cell carcinoma: current status. Drugs 2013, 73(5):427-438.
2. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281.
3. Zietemann V.D., Schuster T., Duell T.H. Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis 2011, 3(2):88-98.
4. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101(23):1642-1649.
5. Burzykowski T., Buyse M., Piccart-Gebhart M.J., et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008, 26(12):1987-1992.
6. Gill S., Berry S., Biagi J., et al. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol 2011, 18(Suppl. 2):S5-S10.
7. Halabi S., Vogelzang N.J., Ou S.S., Owzar K., Archer L., Small E.J. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009, 27(17):2766-2771.
8. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12(10):933-980.
9. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134.
10. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6):1061-1068.
11. Rini B.I., Escudier B., Tomczak, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
12. Heng D.Y., Xie W., Bjarnason G.A., et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011, 117(12):2637-2642.
13. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124.
14. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(33):5422-5428.
15. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-2111.
16. Motzer R.J., Hutson T.E., Cella D., et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med 2013, 369:722-731.
17. Motzer R.J., Nosov D., Eisen T., et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013, 31(30):3791-3799.
18. Rini B.I., Bellmunt J., Clancy J., et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014, 32(8):752-759.
19. Aass N., De Mulder P.H.M., Mickisch G.H.J., et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005, 23(18):4172-4178.
20. De Mulder P.H.M., Oosterhof G.O.N., Bouffioux C., et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. Br J Cancer 1995, 71:371-375.
21. Mc Dermott D.F., Regan M.M., Clark J.I., et al. Randomised phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23(1):133-141.
22. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18(16):2972-2980.
23. Gore M.E., Griffin C.L., Hancock B., et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010, 375(9715):641-648.
24. Liu L., Zhang W., Qi X., et al. Randomised study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012, 18(6):1751-1759.
25. Negrier S., Perol D., Ravaud A., et al. Randomised study of intravenous versus subcutaneous interleukin-2 and IFNα in patients with good prognosis metastatic renal cancer. Clin Cancer Res 2008, 14:5907-5912.
26. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998, 338:1272-1278.
27. Gleave M.E., Elhilali M., Fradet Y., et al. Inteferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998, 18:1265-1271.
28. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116(18):4256-4265.
29. Hutson T.E., Escudier B., Esteban E., et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014, 32(8):760-777.
30. Sargent D.J., Hayes D.F. Assessing the measure of a new drug: is survival the only thing that matters?. J Clin Oncol 2008, 26(12):1922-1923.
31. Delea T.E., Khuu A., Heng D.Y., Haas T., Soulieres D. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer 2012, 107(7):1059-1068.
32. Halabi S., Rini B., Escudier B., et al. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 2014, 120(1):52-60.
33. Hutson T.E., Lesovoy V., Al-Shukri S., et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013, 14(13):1287-1294.
34. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8(4):431-440.